Article

Annals of Surgical Oncology

, Volume 11, Issue 3, pp 208S-210S

NSABP-32: Phase III, randomized trial comparing axillary resection with sentinal lymph node dissection: A description of the trial

  • David N. KragAffiliated withDepartment of Surgery, College of Medicine, University of Vermont Email author 
  • , Thomas B. JulianAffiliated withNational Surgical Breast and Bowel Project
  • , Seth P. HarlowAffiliated withDepartment of Surgery, College of Medicine, University of Vermont
  • , Donald L. WeaverAffiliated withDepartment of Pathology and Medical Statistics, College of Medicine, University of Vermont
  • , Taka AshikagaAffiliated withNational Surgical Breast and Bowel Project
  • , John BryantAffiliated withUiversity of Pittsburgh
  • , Richard M. SingleAffiliated withDepartment of Pathology and Medical Statistics, College of Medicine, University of Vermont
  • , Norman WolmarkAffiliated withNational Surgical Breast and Bowel Project

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

The NSABP-32 trial is a randomized, phase III clinical trial to compare sentinel node (SN) resection to conventional axillary dissection in clinically node-negative breast cancer patients. The primary aims of the trial are to determine if removal of only SNs provides survival and regional control equivalent to those of axillary dissection, while diminishing the magnitude of surgically related side effects. In order to ensure consistency of the outcomes for this trial, a standardized method of SN surgery has been utilized for all cases. A secondary aim of the B32 trial is to evaluate whether patients with “occult” metastases in the SNs have worse survival. Accrual is taking place at 73 institutions in North America, and 217 surgeons are enrolling patients.

Key Words

Breast cancer Clinical trial Sentinel node Survival